ATLANTA, February 3, 2026 — Leads & Copy — Femasys Inc. (NASDAQ: FEMY) has partnered with OR Consulting to launch its product portfolio in Switzerland. The agreement covers FemBloc Permanent Birth Control, FemaSeed Intratubal Insemination, and other Femasys fertility and women’s diagnostic health products.
According to Kathy Lee-Sepsick, Chief Executive Officer and Founder of Femasys Inc., the partnership strengthens Femasys’ European commercial platform and reflects its strategy of building a multi-country footprint through experienced regional partners. Launches of FemBloc are underway in Spain and France.
Christophe Sarzier, Chief Executive Officer of OR Consulting, said Switzerland is an important market for women’s health innovation. He added that the company is excited to support the introduction of FemBloc alongside Femasys’ broader fertility and women’s health solutions. He noted the collaboration reflects a shared commitment to working closely with physicians, navigating complex markets effectively, and expanding access to meaningful options for patients.
Femasys is a biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women. Its portfolio includes FemaSeed® Intratubal Insemination, a first-step infertility treatment, and FemVue®, a companion diagnostic for fallopian tube assessment. Clinical trial data indicates FemaSeed is more than twice as effective as traditional IUI, with a similar safety profile.
FemBloc® permanent birth control is a non-surgical, in-office alternative to surgical sterilization. It received regulatory approval in Europe in June 2025, the UK in August 2025, and New Zealand in September 2025. Strategic partnerships will facilitate commercialization in select European countries. The FemChec® diagnostic product confirms procedural success using ultrasound. Initial clinical trials demonstrated effectiveness, five-year safety, and patient and practitioner satisfaction. Enrollment in the FINALE pivotal trial (NCT05977751) for U.S. FDA approval is ongoing.
OR Consulting is a Switzerland-based medical technology consulting and distribution company that supports surgical and gynecologic solutions. The company draws on experience in the development, commercialization, and clinical support of urogynecologic and pelvic health technologies. OR Consulting is known for physician education, in-procedure clinical support, and market development.
Source: Femasys Inc.
